博贝尔-24在细胞培养和严重联合免疫缺陷小鼠模型中对微小隐孢子虫的活性。
Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
作者信息
Rueda Cristina, Fenoy Soledad, Simón Fernando, Del Aguila Carmen
机构信息
Sección de Parasitología, Departamento de Bioquímica, Biología Celular y Molecular, Facultad de Farmacia, Universidad San Pablo CEU, Urbanización Montepríncipe, Ctra. Boadilla del Monte km 5,300, 28668 Madrid, Spain.
出版信息
Antimicrob Agents Chemother. 2008 Mar;52(3):1150-2. doi: 10.1128/AAC.01019-07. Epub 2007 Dec 26.
Abstract
The anticryptosporidial activity of Bobel-24 (2,4,6-triiodophenol) was studied for the first time, resulting in a reduction of the in vitro growth of Cryptosporidium of up to 99.6%. In a SCID mouse model of chronic cryptosporidiosis, significant differences (P < 0.05) in oocyst shedding were observed in animals treated with 125 mg/kg/day. These results merit further investigation of Bobel-24 as a chemotherapeutic option for cryptosporidiosis.
摘要
首次研究了Bobel-24（2,4,6-三碘苯酚）的抗隐孢子虫活性，结果使隐孢子虫的体外生长减少了高达99.6%。在慢性隐孢子虫病的SCID小鼠模型中，观察到用125毫克/千克/天治疗的动物在卵囊排出方面存在显著差异（P<0.05）。这些结果值得进一步研究将Bobel-24作为隐孢子虫病的一种化疗选择。
相似文献
1
Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
Antimicrob Agents Chemother. 2008 Mar;52(3):1150-2. doi: 10.1128/AAC.01019-07. Epub 2007 Dec 26.
2
Efficacy of chitosan, a natural polysaccharide, against Cryptosporidium parvum in vitro and in vivo in neonatal mice.
Exp Parasitol. 2018 Nov;194:1-8. doi: 10.1016/j.exppara.2018.09.003. Epub 2018 Sep 17.
3
5-Aminopyrazole-4-Carboxamide-Based Compounds Prevent the Growth of Cryptosporidium parvum.
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00020-17. Print 2017 Aug.
4
A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.
PLoS Negl Trop Dis. 2017 Feb 3;11(2):e0005373. doi: 10.1371/journal.pntd.0005373. eCollection 2017 Feb.
5
Inhibitory effect of selenium on Cryptosporidium parvum infection in vitro and in vivo.
Biol Trace Elem Res. 2002 Winter;90(1-3):261-72. doi: 10.1385/BTER:90:1-3:261.
6
Evaluation of in vitro activity of aurones and related compounds against Cryptosporidium parvum.
Planta Med. 2001 Nov;67(8):722-5. doi: 10.1055/s-2001-18357.
7
Substance P receptor antagonism for treatment of cryptosporidiosis in immunosuppressed mice.
J Parasitol. 2008 Oct;94(5):1150-4. doi: 10.1645/GE-1458.1.
8
Quantification of the infectivity of Cryptosporidium parvum by monitoring the oocyst discharge from SCID mice.
Vet Parasitol. 2005 Nov 25;134(1-2):173-6. doi: 10.1016/j.vetpar.2005.06.017. Epub 2005 Aug 1.
9
Dicationic furans inhibit development of Cryptosporidium parvum in HSD/ICR suckling Swiss mice.
J Parasitol. 1998 Aug;84(4):851-6.
10
Efficacy of mangiferin against Cryptosporidium parvum in a neonatal mouse model.
Parasitol Res. 2006 Jul;99(2):184-8. doi: 10.1007/s00436-006-0165-4. Epub 2006 Mar 18.
引用本文的文献
1
Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis.
Antimicrob Agents Chemother. 2014;58(3):1603-14. doi: 10.1128/AAC.02075-13. Epub 2013 Dec 23.
2
Kinetic properties and small-molecule inhibition of human myosin-6.
FEBS Lett. 2012 Sep 21;586(19):3208-14. doi: 10.1016/j.febslet.2012.07.014. Epub 2012 Jul 31.
3
Activity of an anti-inflammatory drug against cryptosporidiosis in neonatal lambs.
Vet Parasitol. 2008 Aug 17;155(3-4):308-13. doi: 10.1016/j.vetpar.2008.05.012. Epub 2008 May 22.
本文引用的文献
1
Dealing with time-dependent pharmacokinetics during the early clinical development of a new leukotriene B4 synthesis inhibitor.
Pharm Res. 2006 Jul;23(7):1533-42. doi: 10.1007/s11095-006-0254-1. Epub 2006 Jun 21.
2
Novel triiodophenol derivatives induce caspase-independent mitochondrial cell death in leukemia cells inhibited by Myc.
Mol Cancer Ther. 2006 May;5(5):1166-75. doi: 10.1158/1535-7163.MCT-05-0257.
3
Interaction of Cryptosporidium hominis and Cryptosporidium parvum with primary human and bovine intestinal cells.
Infect Immun. 2006 Jan;74(1):99-107. doi: 10.1128/IAI.74.1.99-107.2006.
4
Cryptosporidium and cryptosporidiosis.
Adv Parasitol. 2005;59:77-158. doi: 10.1016/S0065-308X(05)59002-X.
5
In vitro and in vivo analysis of the thyroid disrupting activities of phenolic and phenol compounds in Xenopus laevis.
Toxicol Sci. 2005 Mar;84(1):29-37. doi: 10.1093/toxsci/kfi049. Epub 2004 Dec 8.
6
In vitro cultivation of cryptosporidium species.
Clin Microbiol Rev. 2002 Jul;15(3):390-400. doi: 10.1128/CMR.15.3.390-400.2002.
7
Mechanisms of attachment and internalization of Cryptosporidium parvum to biliary and intestinal epithelial cells.
Gastroenterology. 2000 Feb;118(2):368-79. doi: 10.1016/s0016-5085(00)70219-8.
8
Pathogenesis of Cryptosporidium parvum infection.
Microbes Infect. 1999 Feb;1(2):141-8. doi: 10.1016/s1286-4579(99)80005-7.
9
Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models.
Antimicrob Agents Chemother. 1998 Aug;42(8):1959-65. doi: 10.1128/AAC.42.8.1959.
10
High-performance liquid chromatography analysis of Bobel-24 in biological samples for pharmacokinetic, metabolic and tissue distribution studies.
J Chromatogr B Biomed Sci Appl. 1998 Apr 24;708(1-2):169-75. doi: 10.1016/s0378-4347(97)00645-2.
Zotero 插件